• Justin Bekelman

Justin E. Bekelman, MD

Biosketch

Dr. Bekelman leads research programs in cancer health services, comparative effectiveness and delivery system and payment reform. His research integrates methods from the fields of epidemiology, clinical trials, health economics and public policy. Dr. Bekelman conducts research to examine the quality, comparative effectiveness, and costs of treatments for prevalent cancers using registry, Medicare, and commercial payer administrative claims data and co-leads the multicenter PARTIQoL randomized trial, which compares patient-reported outcomes after proton therapy versus intensity-modulated radiotherapy (IMRT) for prostate cancer. Dr. Bekelman has received research funding from the National Cancer Institute, the American Cancer Society, and philanthropic sources. He did his undergraduate work at Princeton University in the Woodrow Wilson School of Public and International Affairs and his medical training at Yale University, Johns Hopkins, and Memorial Sloan Kettering Cancer Center. Dr. Bekelman formerly served as Special Assistant to the Under Secretary of Defense in the US Department of Defense. He is a board-certified radiation oncologist and practicing physician at the University of Pennsylvania Perelman School of Medicine.

Selected Publications

Bekelman JE, Epstein A, Emanuel EJ:

2014. Getting the Next Version of Payment Policy "Right" on the Road Toward Accountable Cancer Care. Int J Radiat Oncol Biol Phys. In press.

Bekelman JE, Asch DA, Tochner Z, Friedberg J, Vaughn DJ, Rash E, Raksowski K, Hahn SM:

2014. Principles and Reality of Proton Therapy Treatment Allocation Int J Radiat Oncol Biol Phys.

Bekelman JE, Hahn SM:

2014. Reference Pricing with Evidence Development-A Way Forward for Proton Therapy. Journal of Clinical Oncology. 32(15):1540-2.

Bekelman JE, Kim M, Emanuel EJ:

2013. Toward Accountable Cancer Care. JAMA Internal Medicine 173(11): 958-9, June.

Bekelman JE, Epstein AJ, Emanuel EJ:

2013. Single vs Multiple Fraction Radiotherapy for Bone Metastases from Prostate Cancer. JAMA 310(14): 1501-02, Oct.

Bekelman JE, Suneja G, Guzzo T, Pollack CE, Armstrong K, Epstein AJ:

2013. Effect of Practice Integration between Urologists and Radiation Oncologistson Prostate Cancer Treatment Patterns. Journal of Urology 190(1): 97-101, Jul.

Bekelman JE, Handorf EA, Guzzo T, Pollack CE, Christodouleas J, Resnick MJ, Swisher McClure S, Vaughn D, Ten Have T, Polsky D, Mitra N:

2013. Radical Cystectomy versus Bladder Preserving Therapy for Muscle-Invasive Urothelial Carcinoma: Examining Confounding and Misclassification Bias in Cancer Observational Comparative Effectiveness Research. Value in Health 16(4): 610-8, Jun.

Bekelman JE, Shah A, Hahn S:

2011. Implications of Comparative Effectiveness Research for Radiation Oncology. Practical Radiation Oncology 1(2): 72-80.

Bekelman JE, Mitra N, Efstathiou N, Liao K, Sunderland R, Yeboa DN, Armstrong K:

2011. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 81(4): e325-34.

Bekelman JE, Li Y, Gross C:

2003. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289: 454-465.

Education

MD, Yale University School of Medicine

AB, Princeton University